Artiva Biotherapeutics, Inc. ARTV Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Returns | |||
| Return on equity | -56.5%— | —— | |
| Return on assets | -49.3%-7.7pp | -41.5%— | |
| Return on invested capital | -70.6%— | —— | |
| Efficiency | |||
| Asset turnover | 0×— | —— | |
| Liquidity | |||
| Current ratio | 8.6×-6.8× | 15.4×+8.9× | |
| Quick ratio | 8.6×-6.8× | 15.4×+8.9× | |
| Cash ratio | 2.1×-1.2× | 3.3×-1.1× | |
| Leverage | |||
| Debt-to-equity | 0.1×0.0× | 0.1×— | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | |
| Per Share | |||
| Book value per share | $4.50-72.9% | $16.58+108% | |
| Valuation | |||
| Market capitalization | $429.03M+1,015% | $244.84M— | |
| Enterprise value | $417.88M+1,832% | $218.7M— | |
| Price / book | 4.9×+4.7× | 1.3×— | |
| Free cash flow yield | -18.7%+140pp | -22.7%— | |
| Earnings yield | -20.3%+166pp | -26.7%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Artiva Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Artiva Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.